Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, randomized, double-blind, multicenter dose-ranging study to evaluate the
safety, tolerability, and PK of NX-13. Approximately 40 subjects will be randomized in a
3:3:3:1 ratio to receive 1 of 3 NX-13 treatment regimens (NX-13 250 mg IR, 500 mg IR, 500 mg
MR) (12 evaluable subjects at each of the 3 dose levels) or placebo (4 subjects), once daily
for 28 consecutive days.